Inhibitory receptor CD47 binding to plasma TSP1 suppresses NK-cell IFN-γ production via activating the JAK/STAT3 pathway during HIV infection
Natural killer (NK) cells play an important first-line role against tumour and viral infections and are regulated by inhibitory receptor expression. Among these inhibitory receptors, the expression, function, and mechanism of cluster of differentiation 47 (CD47) on NK cells during human immunodefici...
Saved in:
Published in | Journal of translational medicine Vol. 21; no. 1; pp. 869 - 13 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central
30.11.2023
BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Natural killer (NK) cells play an important first-line role against tumour and viral infections and are regulated by inhibitory receptor expression. Among these inhibitory receptors, the expression, function, and mechanism of cluster of differentiation 47 (CD47) on NK cells during human immunodeficiency virus (HIV) infection remain unclear.
Fresh peripheral blood mononuclear cells (PBMCs) were collected from people living with HIV (PLWH) and HIV negative controls (NC) subjects. Soluble ligand expression levels of CD47 were measured using ELISA. HIV viral proteins or Toll-like receptor 7/8 (TLR7/8) agonist was used to investigate the mechanisms underlying the upregulation of CD47 expression. The effect of CD47 on NK cell activation, proliferation, and function were evaluated by flow cytometry. RNA-seq was used to identify downstream pathways for CD47 and its ligand interactions. A small molecule inhibitor was used to restore the inhibition of NK cell function by CD47 signalling.
CD47 expression was highly upregulated on the NK cells from PLWH, which could be due to activation of the Toll-like receptor 7/8 (TLR7/8) pathway. Compared with NC subjects, PLWH subjects exhibited elevated levels of CD47 ligands, thrombospondin-1 (TSP1), and counter ligand signal regulatory protein-α (SIRPα). The TSP1-CD47 axis drives the suppression of interferon gamma (IFN-γ) production and the activation of the Janus kinase signal transducer and activator of transcription (JAK-STAT) pathway in NK cells. After treatment with a STAT3 inhibitor, the NK cells from PLWH showed significantly improved IFN-γ production.
The current data indicate that the binding of the inhibitory receptor CD47 to plasma TSP1 suppresses NK cell IFN-γ production by activating the JAK/STAT3 pathway during HIV infection. Our results suggest that CD47 and its related signalling pathways could be targets for improving NK cell function in people living with HIV. |
---|---|
AbstractList | Abstract Background Natural killer (NK) cells play an important first-line role against tumour and viral infections and are regulated by inhibitory receptor expression. Among these inhibitory receptors, the expression, function, and mechanism of cluster of differentiation 47 (CD47) on NK cells during human immunodeficiency virus (HIV) infection remain unclear. Methods Fresh peripheral blood mononuclear cells (PBMCs) were collected from people living with HIV (PLWH) and HIV negative controls (NC) subjects. Soluble ligand expression levels of CD47 were measured using ELISA. HIV viral proteins or Toll-like receptor 7/8 (TLR7/8) agonist was used to investigate the mechanisms underlying the upregulation of CD47 expression. The effect of CD47 on NK cell activation, proliferation, and function were evaluated by flow cytometry. RNA-seq was used to identify downstream pathways for CD47 and its ligand interactions. A small molecule inhibitor was used to restore the inhibition of NK cell function by CD47 signalling. Results CD47 expression was highly upregulated on the NK cells from PLWH, which could be due to activation of the Toll-like receptor 7/8 (TLR7/8) pathway. Compared with NC subjects, PLWH subjects exhibited elevated levels of CD47 ligands, thrombospondin-1 (TSP1), and counter ligand signal regulatory protein-α (SIRPα). The TSP1–CD47 axis drives the suppression of interferon gamma (IFN-γ) production and the activation of the Janus kinase signal transducer and activator of transcription (JAK–STAT) pathway in NK cells. After treatment with a STAT3 inhibitor, the NK cells from PLWH showed significantly improved IFN-γ production. Conclusions The current data indicate that the binding of the inhibitory receptor CD47 to plasma TSP1 suppresses NK cell IFN-γ production by activating the JAK/STAT3 pathway during HIV infection. Our results suggest that CD47 and its related signalling pathways could be targets for improving NK cell function in people living with HIV. Natural killer (NK) cells play an important first-line role against tumour and viral infections and are regulated by inhibitory receptor expression. Among these inhibitory receptors, the expression, function, and mechanism of cluster of differentiation 47 (CD47) on NK cells during human immunodeficiency virus (HIV) infection remain unclear.BACKGROUNDNatural killer (NK) cells play an important first-line role against tumour and viral infections and are regulated by inhibitory receptor expression. Among these inhibitory receptors, the expression, function, and mechanism of cluster of differentiation 47 (CD47) on NK cells during human immunodeficiency virus (HIV) infection remain unclear.Fresh peripheral blood mononuclear cells (PBMCs) were collected from people living with HIV (PLWH) and HIV negative controls (NC) subjects. Soluble ligand expression levels of CD47 were measured using ELISA. HIV viral proteins or Toll-like receptor 7/8 (TLR7/8) agonist was used to investigate the mechanisms underlying the upregulation of CD47 expression. The effect of CD47 on NK cell activation, proliferation, and function were evaluated by flow cytometry. RNA-seq was used to identify downstream pathways for CD47 and its ligand interactions. A small molecule inhibitor was used to restore the inhibition of NK cell function by CD47 signalling.METHODSFresh peripheral blood mononuclear cells (PBMCs) were collected from people living with HIV (PLWH) and HIV negative controls (NC) subjects. Soluble ligand expression levels of CD47 were measured using ELISA. HIV viral proteins or Toll-like receptor 7/8 (TLR7/8) agonist was used to investigate the mechanisms underlying the upregulation of CD47 expression. The effect of CD47 on NK cell activation, proliferation, and function were evaluated by flow cytometry. RNA-seq was used to identify downstream pathways for CD47 and its ligand interactions. A small molecule inhibitor was used to restore the inhibition of NK cell function by CD47 signalling.CD47 expression was highly upregulated on the NK cells from PLWH, which could be due to activation of the Toll-like receptor 7/8 (TLR7/8) pathway. Compared with NC subjects, PLWH subjects exhibited elevated levels of CD47 ligands, thrombospondin-1 (TSP1), and counter ligand signal regulatory protein-α (SIRPα). The TSP1-CD47 axis drives the suppression of interferon gamma (IFN-γ) production and the activation of the Janus kinase signal transducer and activator of transcription (JAK-STAT) pathway in NK cells. After treatment with a STAT3 inhibitor, the NK cells from PLWH showed significantly improved IFN-γ production.RESULTSCD47 expression was highly upregulated on the NK cells from PLWH, which could be due to activation of the Toll-like receptor 7/8 (TLR7/8) pathway. Compared with NC subjects, PLWH subjects exhibited elevated levels of CD47 ligands, thrombospondin-1 (TSP1), and counter ligand signal regulatory protein-α (SIRPα). The TSP1-CD47 axis drives the suppression of interferon gamma (IFN-γ) production and the activation of the Janus kinase signal transducer and activator of transcription (JAK-STAT) pathway in NK cells. After treatment with a STAT3 inhibitor, the NK cells from PLWH showed significantly improved IFN-γ production.The current data indicate that the binding of the inhibitory receptor CD47 to plasma TSP1 suppresses NK cell IFN-γ production by activating the JAK/STAT3 pathway during HIV infection. Our results suggest that CD47 and its related signalling pathways could be targets for improving NK cell function in people living with HIV.CONCLUSIONSThe current data indicate that the binding of the inhibitory receptor CD47 to plasma TSP1 suppresses NK cell IFN-γ production by activating the JAK/STAT3 pathway during HIV infection. Our results suggest that CD47 and its related signalling pathways could be targets for improving NK cell function in people living with HIV. Natural killer (NK) cells play an important first-line role against tumour and viral infections and are regulated by inhibitory receptor expression. Among these inhibitory receptors, the expression, function, and mechanism of cluster of differentiation 47 (CD47) on NK cells during human immunodeficiency virus (HIV) infection remain unclear. Fresh peripheral blood mononuclear cells (PBMCs) were collected from people living with HIV (PLWH) and HIV negative controls (NC) subjects. Soluble ligand expression levels of CD47 were measured using ELISA. HIV viral proteins or Toll-like receptor 7/8 (TLR7/8) agonist was used to investigate the mechanisms underlying the upregulation of CD47 expression. The effect of CD47 on NK cell activation, proliferation, and function were evaluated by flow cytometry. RNA-seq was used to identify downstream pathways for CD47 and its ligand interactions. A small molecule inhibitor was used to restore the inhibition of NK cell function by CD47 signalling. CD47 expression was highly upregulated on the NK cells from PLWH, which could be due to activation of the Toll-like receptor 7/8 (TLR7/8) pathway. Compared with NC subjects, PLWH subjects exhibited elevated levels of CD47 ligands, thrombospondin-1 (TSP1), and counter ligand signal regulatory protein-α (SIRPα). The TSP1-CD47 axis drives the suppression of interferon gamma (IFN-γ) production and the activation of the Janus kinase signal transducer and activator of transcription (JAK-STAT) pathway in NK cells. After treatment with a STAT3 inhibitor, the NK cells from PLWH showed significantly improved IFN-γ production. The current data indicate that the binding of the inhibitory receptor CD47 to plasma TSP1 suppresses NK cell IFN-γ production by activating the JAK/STAT3 pathway during HIV infection. Our results suggest that CD47 and its related signalling pathways could be targets for improving NK cell function in people living with HIV. BackgroundNatural killer (NK) cells play an important first-line role against tumour and viral infections and are regulated by inhibitory receptor expression. Among these inhibitory receptors, the expression, function, and mechanism of cluster of differentiation 47 (CD47) on NK cells during human immunodeficiency virus (HIV) infection remain unclear.MethodsFresh peripheral blood mononuclear cells (PBMCs) were collected from people living with HIV (PLWH) and HIV negative controls (NC) subjects. Soluble ligand expression levels of CD47 were measured using ELISA. HIV viral proteins or Toll-like receptor 7/8 (TLR7/8) agonist was used to investigate the mechanisms underlying the upregulation of CD47 expression. The effect of CD47 on NK cell activation, proliferation, and function were evaluated by flow cytometry. RNA-seq was used to identify downstream pathways for CD47 and its ligand interactions. A small molecule inhibitor was used to restore the inhibition of NK cell function by CD47 signalling.ResultsCD47 expression was highly upregulated on the NK cells from PLWH, which could be due to activation of the Toll-like receptor 7/8 (TLR7/8) pathway. Compared with NC subjects, PLWH subjects exhibited elevated levels of CD47 ligands, thrombospondin-1 (TSP1), and counter ligand signal regulatory protein-α (SIRPα). The TSP1–CD47 axis drives the suppression of interferon gamma (IFN-γ) production and the activation of the Janus kinase signal transducer and activator of transcription (JAK–STAT) pathway in NK cells. After treatment with a STAT3 inhibitor, the NK cells from PLWH showed significantly improved IFN-γ production.ConclusionsThe current data indicate that the binding of the inhibitory receptor CD47 to plasma TSP1 suppresses NK cell IFN-γ production by activating the JAK/STAT3 pathway during HIV infection. Our results suggest that CD47 and its related signalling pathways could be targets for improving NK cell function in people living with HIV. |
ArticleNumber | 869 |
Author | Wang, Meiting Hu, Qinghai Jiang, Yongjun Zhang, Zining Lang, Bin Ding, Haibo Fu, Yajing Han, Xiaoxu Shang, Hong |
Author_xml | – sequence: 1 givenname: Bin surname: Lang fullname: Lang, Bin – sequence: 2 givenname: Meiting surname: Wang fullname: Wang, Meiting – sequence: 3 givenname: Zining surname: Zhang fullname: Zhang, Zining – sequence: 4 givenname: Yajing surname: Fu fullname: Fu, Yajing – sequence: 5 givenname: Xiaoxu surname: Han fullname: Han, Xiaoxu – sequence: 6 givenname: Qinghai surname: Hu fullname: Hu, Qinghai – sequence: 7 givenname: Haibo surname: Ding fullname: Ding, Haibo – sequence: 8 givenname: Hong orcidid: 0000-0002-8907-8124 surname: Shang fullname: Shang, Hong – sequence: 9 givenname: Yongjun surname: Jiang fullname: Jiang, Yongjun |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38037074$$D View this record in MEDLINE/PubMed |
BookMark | eNp9ks9u1DAQxiNURP_AC3BAlrhwCbUd27FPqFooXVoVpC5crYnj7HqVjVM7WbQvwcvwHjwT3t1StT1wmk-eb34az8xxdtD5zmbZa4LfEyLFaSRUiTLHtMgxE0mJZ9kRYaXKuSzFwQN9mB3HuMSYMs7Ui-ywkLgoccmOsl_TbuEqN_iwQcEa2yeFJh9ZiSrX1a6bo8GjvoW4AjS7-UZQHPs-2BhtRNeXubFti6bn1_mf36gPvh7N4HyH1g4QJLmGYYdYWPTl7PL0ZnY2K1APw-InbFA9hm3yYvoDua6xu8qX2fMG2mhf3cWT7Pv5p9nkIr_6-nk6ObvKDVPlkBcKSqAVL6qkGKdEGFlbDrW1zMoKamAlVJyrqgTTGMPLihtay1owSnglipNsuufWHpa6D24FYaM9OL178GGuIQzOtFZbqQqhGsKwMIwQooxKUTYNNdwWGBLrw57Vj9XK1sZ2Q4D2EfRxpnMLPfdrTbCQEqsiEd7dEYK_HW0c9MrF7Wihs36MmkolJKaS8GR9-8S69GPo0qw0VZiSQnK-Bb552NJ9L__2ngx0bzDBxxhsc28hWG-PS--PS6fj0rvj0tuhySdFxg2wXVv6lmv_V_oXbhPUog |
CitedBy_id | crossref_primary_10_1016_j_apsb_2024_11_018 crossref_primary_10_1002_mc_23855 crossref_primary_10_3390_v17030309 |
Cites_doi | 10.1084/jem.20200839 10.1146/annurev.iy.02.040184.002143 10.1128/JVI.77.4.2663-2674.2003 10.3390/cancers6020926 10.1016/j.canlet.2021.09.028 10.1128/jvi.65.11.6277-6282.1991 10.1016/j.ejca.2022.02.009 10.3390/cancers13246229 10.1016/j.it.2017.12.005 10.1038/s41541-022-00477-x 10.1182/blood-2007-08-105965 10.3389/fmicb.2023.1033448 10.1200/JCO.19.00121 10.1146/annurev-immunol-032712-100001 10.1016/0161-5890(94)90092-2 10.1038/s41590-021-00943-z 10.1158/2159-8290.CD-21-0407 10.1016/j.cell.2020.01.022 10.3389/fimmu.2021.792775 10.1189/jlb.69.6.912 10.1158/0008-5472.CAN-20-2426 10.1158/2326-6066.CIR-18-0367 10.4049/jimmunol.177.6.3534 10.1159/000132568 10.1053/j.seminoncol.2020.05.009 10.1097/01.cji.0000211327.76266.65 10.1001/jama.2016.4059 10.1073/pnas.0507484102 10.1128/mBio.01293-20 10.1016/j.yexcr.2015.07.007 10.1056/NEJMoa1305133 10.1111/imr.12524 10.1016/j.immuni.2016.05.001 10.1074/jbc.M110.179663 10.3389/fimmu.2018.00474 10.3390/biom13050748 10.1038/s41586-018-0600-6 10.1038/s41467-022-31196-5 10.1186/s12865-021-00417-9 10.1038/ncomms14802 10.1111/imr.12519 10.1016/j.immuni.2020.04.011 10.1155/2015/178698 10.1182/blood-2014-03-564450 10.1242/jcs.108.11.3419 10.1126/sciimmunol.abb1025 10.4049/jimmunol.1900856 10.1128/jvi.67.5.2844-2852.1993 |
ContentType | Journal Article |
Copyright | 2023. The Author(s). 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2023 |
Copyright_xml | – notice: 2023. The Author(s). – notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2023 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7T5 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM DOA |
DOI | 10.1186/s12967-023-04667-6 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1479-5876 |
EndPage | 13 |
ExternalDocumentID | oai_doaj_org_article_e89369f1406c41119c9c418ff2c5e30a PMC10688093 38037074 10_1186_s12967_023_04667_6 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | China |
GeographicLocations_xml | – name: China |
GrantInformation_xml | – fundername: the China 13th Five-Year Plan of National Science Research grantid: 2017ZX10201101 – fundername: Scientific Research Project of Higher Education in Liaoning province grantid: LJKZ0737 – fundername: The National Key Research and Development Program of China grantid: 2021YFC2301802 – fundername: Science and Technology Innovation Team of China Medical University grantid: CXTD2022003 – fundername: ; grantid: LJKZ0737 – fundername: ; grantid: CXTD2022003 – fundername: ; grantid: 2017ZX10201101 – fundername: ; grantid: 2021YFC2301802 |
GroupedDBID | --- 0R~ 29L 2WC 53G 5VS 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP WOQ WOW XSB ~8M -A0 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF NPM 7T5 7XB 8FK AZQEC DWQXO H94 K9. PJZUB PKEHL PPXIY PQEST PQUKI 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c497t-39a7a2b53b39a45216c8de5adee4e8bada47ab559b7acfcc57b5c2d8d64215b63 |
IEDL.DBID | M48 |
ISSN | 1479-5876 |
IngestDate | Wed Aug 27 00:58:29 EDT 2025 Thu Aug 21 18:35:49 EDT 2025 Fri Jul 11 10:27:33 EDT 2025 Sat Jul 26 00:12:47 EDT 2025 Thu Jan 02 22:27:17 EST 2025 Tue Jul 01 02:59:42 EDT 2025 Thu Apr 24 23:10:22 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | JAK–STAT3 IFN-γ NK cells CD47 HIV infection TSP1 |
Language | English |
License | 2023. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c497t-39a7a2b53b39a45216c8de5adee4e8bada47ab559b7acfcc57b5c2d8d64215b63 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0002-8907-8124 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12967-023-04667-6 |
PMID | 38037074 |
PQID | 2902138553 |
PQPubID | 43076 |
PageCount | 13 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_e89369f1406c41119c9c418ff2c5e30a pubmedcentral_primary_oai_pubmedcentral_nih_gov_10688093 proquest_miscellaneous_2896802815 proquest_journals_2902138553 pubmed_primary_38037074 crossref_primary_10_1186_s12967_023_04667_6 crossref_citationtrail_10_1186_s12967_023_04667_6 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2023-11-30 |
PublicationDateYYYYMMDD | 2023-11-30 |
PublicationDate_xml | – month: 11 year: 2023 text: 2023-11-30 day: 30 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Journal of translational medicine |
PublicationTitleAlternate | J Transl Med |
PublicationYear | 2023 |
Publisher | BioMed Central BMC |
Publisher_xml | – name: BioMed Central – name: BMC |
References | 4667_CR20 4667_CR41 4667_CR26 L Ni (4667_CR2) 2017; 276 P Betancur (4667_CR31) 2017; 8 D Gotthardt (4667_CR48) 2014; 124 O Hamid (4667_CR9) 2013; 369 P Nath (4667_CR24) 2019; 7 N Oyaizu (4667_CR29) 1991; 65 A Ribas (4667_CR10) 2016; 315 C Carlino (4667_CR40) 2008; 111 N Dizman (4667_CR14) 2021; 13 M Reinhold (4667_CR11) 1995; 108 M Kortylewski (4667_CR46) 2007; 30 S Kaur (4667_CR17) 2011; 286 N Jacquelot (4667_CR4) 2021; 22 M Kim (4667_CR25) 2008; 29 C Fionda (4667_CR47) 2015; 2015 L Andrews (4667_CR3) 2017; 276 S Rinaldi (4667_CR28) 2020; 204 E Borducchi (4667_CR38) 2018; 563 D Peppa (4667_CR23) 2018; 9 S Jost (4667_CR22) 2013; 31 A Anderson (4667_CR1) 2016; 44 J Ventura (4667_CR36) 2022; 7 Y Chen (4667_CR33) 1994; 31 B Oronsky (4667_CR15) 2020; 47 P Grimbert (4667_CR18) 2006; 177 A Veillette (4667_CR13) 2018; 39 4667_CR35 A Veillette (4667_CR16) 2019; 37 U Wille-Reece (4667_CR43) 2005; 102 M de Veer (4667_CR32) 2001; 69 V Walker-Sperling (4667_CR39) 2022; 13 X Yu (4667_CR21) 2021; 22 P Adusumilli (4667_CR7) 2021; 11 M Tal (4667_CR19) 2020; 11 M Logtenberg (4667_CR12) 2020; 52 Y Li (4667_CR37) 2023; 14 P Xu (4667_CR45) 2015; 337 A Xiong (4667_CR44) 2014; 6 E Unanue (4667_CR27) 1984; 2 W Shi (4667_CR6) 2021; 522 Y Adachi (4667_CR5) 2022; 82 C Jassoy (4667_CR30) 1993; 67 U Malhotra (4667_CR34) 2003; 77 P Dogra (4667_CR42) 2020; 180 M Kudo (4667_CR8) 2022; 167 |
References_xml | – ident: 4667_CR20 doi: 10.1084/jem.20200839 – volume: 2 start-page: 395 year: 1984 ident: 4667_CR27 publication-title: Annual Rev Immunol. doi: 10.1146/annurev.iy.02.040184.002143 – volume: 77 start-page: 2663 issue: 4 year: 2003 ident: 4667_CR34 publication-title: J Virol. doi: 10.1128/JVI.77.4.2663-2674.2003 – volume: 6 start-page: 926 issue: 2 year: 2014 ident: 4667_CR44 publication-title: Cancers. doi: 10.3390/cancers6020926 – volume: 522 start-page: 184 year: 2021 ident: 4667_CR6 publication-title: Cancer Lett doi: 10.1016/j.canlet.2021.09.028 – volume: 65 start-page: 6277 issue: 11 year: 1991 ident: 4667_CR29 publication-title: J Virol doi: 10.1128/jvi.65.11.6277-6282.1991 – volume: 167 start-page: 1 year: 2022 ident: 4667_CR8 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2022.02.009 – volume: 13 start-page: 6229 issue: 24 year: 2021 ident: 4667_CR14 publication-title: Cancers doi: 10.3390/cancers13246229 – volume: 39 start-page: 173 issue: 3 year: 2018 ident: 4667_CR13 publication-title: Trends Immunol doi: 10.1016/j.it.2017.12.005 – volume: 7 start-page: 53 issue: 1 year: 2022 ident: 4667_CR36 publication-title: NPJ Vaccines. doi: 10.1038/s41541-022-00477-x – volume: 111 start-page: 3108 issue: 6 year: 2008 ident: 4667_CR40 publication-title: Blood. doi: 10.1182/blood-2007-08-105965 – volume: 14 start-page: 1033448 year: 2023 ident: 4667_CR37 publication-title: Front Microbiol. doi: 10.3389/fmicb.2023.1033448 – volume: 37 start-page: 1012 issue: 12 year: 2019 ident: 4667_CR16 publication-title: J Clin Oncol doi: 10.1200/JCO.19.00121 – volume: 31 start-page: 163 year: 2013 ident: 4667_CR22 publication-title: Annu Rev Immunol. doi: 10.1146/annurev-immunol-032712-100001 – volume: 31 start-page: 977 issue: 13 year: 1994 ident: 4667_CR33 publication-title: Mol Immunol. doi: 10.1016/0161-5890(94)90092-2 – volume: 22 start-page: 851 issue: 7 year: 2021 ident: 4667_CR4 publication-title: Nat Immunol doi: 10.1038/s41590-021-00943-z – volume: 11 start-page: 2748 issue: 11 year: 2021 ident: 4667_CR7 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-21-0407 – volume: 180 start-page: 749 issue: 4 year: 2020 ident: 4667_CR42 publication-title: Cell. doi: 10.1016/j.cell.2020.01.022 – ident: 4667_CR26 doi: 10.3389/fimmu.2021.792775 – volume: 69 start-page: 912 issue: 6 year: 2001 ident: 4667_CR32 publication-title: J Leukoc Biol. doi: 10.1189/jlb.69.6.912 – volume: 82 start-page: 292 issue: 2 year: 2022 ident: 4667_CR5 publication-title: Can Res doi: 10.1158/0008-5472.CAN-20-2426 – volume: 7 start-page: 1547 issue: 9 year: 2019 ident: 4667_CR24 publication-title: Cancer Immunol Res. doi: 10.1158/2326-6066.CIR-18-0367 – volume: 177 start-page: 3534 issue: 6 year: 2006 ident: 4667_CR18 publication-title: J Immunol doi: 10.4049/jimmunol.177.6.3534 – volume: 29 start-page: 28 issue: 1 year: 2008 ident: 4667_CR25 publication-title: Tumour Biol. doi: 10.1159/000132568 – volume: 47 start-page: 117 year: 2020 ident: 4667_CR15 publication-title: Semin Oncol doi: 10.1053/j.seminoncol.2020.05.009 – volume: 30 start-page: 131 issue: 2 year: 2007 ident: 4667_CR46 publication-title: J Immunother. doi: 10.1097/01.cji.0000211327.76266.65 – volume: 315 start-page: 1600 issue: 15 year: 2016 ident: 4667_CR10 publication-title: JAMA doi: 10.1001/jama.2016.4059 – volume: 102 start-page: 15190 issue: 42 year: 2005 ident: 4667_CR43 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0507484102 – volume: 11 start-page: 10 issue: 3 year: 2020 ident: 4667_CR19 publication-title: MBio. doi: 10.1128/mBio.01293-20 – volume: 337 start-page: 53 issue: 1 year: 2015 ident: 4667_CR45 publication-title: Exp Cell Res. doi: 10.1016/j.yexcr.2015.07.007 – volume: 369 start-page: 134 issue: 2 year: 2013 ident: 4667_CR9 publication-title: N Engl J Med doi: 10.1056/NEJMoa1305133 – volume: 276 start-page: 52 issue: 1 year: 2017 ident: 4667_CR2 publication-title: Immunol Rev doi: 10.1111/imr.12524 – volume: 44 start-page: 989 issue: 5 year: 2016 ident: 4667_CR1 publication-title: Immunity doi: 10.1016/j.immuni.2016.05.001 – volume: 286 start-page: 14991 issue: 17 year: 2011 ident: 4667_CR17 publication-title: J Biol Chem doi: 10.1074/jbc.M110.179663 – volume: 9 start-page: 474 year: 2018 ident: 4667_CR23 publication-title: Front Immunol. doi: 10.3389/fimmu.2018.00474 – ident: 4667_CR41 doi: 10.3390/biom13050748 – volume: 563 start-page: 360 issue: 7731 year: 2018 ident: 4667_CR38 publication-title: Nature. doi: 10.1038/s41586-018-0600-6 – volume: 13 start-page: 3463 issue: 1 year: 2022 ident: 4667_CR39 publication-title: Nat Commun. doi: 10.1038/s41467-022-31196-5 – volume: 22 start-page: 25 issue: 1 year: 2021 ident: 4667_CR21 publication-title: BMC Immunol. doi: 10.1186/s12865-021-00417-9 – volume: 8 start-page: 14802 year: 2017 ident: 4667_CR31 publication-title: Nat Commun. doi: 10.1038/ncomms14802 – volume: 276 start-page: 80 issue: 1 year: 2017 ident: 4667_CR3 publication-title: Immunol Rev doi: 10.1111/imr.12519 – volume: 52 start-page: 742 issue: 5 year: 2020 ident: 4667_CR12 publication-title: Immunity doi: 10.1016/j.immuni.2020.04.011 – volume: 2015 start-page: 178698 year: 2015 ident: 4667_CR47 publication-title: Biomed Res Int doi: 10.1155/2015/178698 – volume: 124 start-page: 2370 issue: 15 year: 2014 ident: 4667_CR48 publication-title: Blood. doi: 10.1182/blood-2014-03-564450 – volume: 108 start-page: 3419 year: 1995 ident: 4667_CR11 publication-title: J Cell Sci doi: 10.1242/jcs.108.11.3419 – ident: 4667_CR35 doi: 10.1126/sciimmunol.abb1025 – volume: 204 start-page: 540 issue: 3 year: 2020 ident: 4667_CR28 publication-title: J Immunol (Baltimore, Md: 1950) doi: 10.4049/jimmunol.1900856 – volume: 67 start-page: 2844 issue: 5 year: 1993 ident: 4667_CR30 publication-title: J Virol. doi: 10.1128/jvi.67.5.2844-2852.1993 |
SSID | ssj0024549 |
Score | 2.410172 |
Snippet | Natural killer (NK) cells play an important first-line role against tumour and viral infections and are regulated by inhibitory receptor expression. Among... BackgroundNatural killer (NK) cells play an important first-line role against tumour and viral infections and are regulated by inhibitory receptor expression.... Abstract Background Natural killer (NK) cells play an important first-line role against tumour and viral infections and are regulated by inhibitory receptor... |
SourceID | doaj pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 869 |
SubjectTerms | Antibodies CD47 CD47 Antigen Cell activation Cell differentiation Enzyme-linked immunosorbent assay Flow cytometry HIV HIV infection HIV Infections Human immunodeficiency virus Humans IFN-γ Infections Interferon-gamma - metabolism JAK–STAT3 Janus kinase Janus Kinases - metabolism Killer Cells, Natural - metabolism Leukocytes (mononuclear) Leukocytes, Mononuclear - metabolism Ligands Lymphocytes Natural killer cells NK cells Peripheral blood mononuclear cells Phosphorylation Plasma Proteins Receptor mechanisms Signal regulatory protein-α Signal transduction Software Stat3 protein STAT3 Transcription Factor - metabolism Thrombospondin TLR7 protein Toll-Like Receptor 7 Toll-like receptors TSP1 γ-Interferon |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NjtMwELbQHlZcECx_gQUNEjcUNYl_4hzL7lbtrrZC2i7am2U7jhppSSPagngJXob34JkYO0m1RQgunGo1TuVmZjzfODPfEPLWaVEhUE7j1FIMUDJnY60rFldWJlpnunTOn0NezsX0mp3f8Js7rb58TlhHD9w9uJGTvuVchXGAsAwNs7AFfsqqyix3NAnQCH3eEEwNLHsY9gwlMlKM1ujVcENA_-RTGXEk9txQYOv_E8T8PVPyjuuZPCQPeswI426tj8g91xyRw8v-rfhj8n3WLGtT-9flgBuYa3EEJ6csB1OHohXYrKBFmPxJw-LqQwrrbRvyX90a5hexP7uH2WQe__wBbUcAi8KCL7UGX_Xgz2z9TywdnI8vRleL8YKCb2T8VX-DrsoRprOPMKR1NU_I9eRscTKN-z4LsWVFvolpoXOdGU4Njhj6c2Fl6XiQk5NGl5rl2mDoYXJtK2t5brjNSln6IlluBH1KDppV454TQPSH8RRCNgSCuBsUUugqYTlliWWl5iIi6fDYle1JyH0vjFsVghEpVCcqhaJSQVQK73m3u6ftKDj-Ovu9l-ZupqfPDl-gUqleqdS_lCoix4MuqN6m1yorEA9RyTmNyJvdZbRGLybduNUW58hCSIRsKY_Is051diuhMqE5IraIyD2l2lvq_pWmXgbG79S3BkoK-uJ__LmX5H7mLSHwVx6Tg83nrXuFyGpjXgcj-gVfKR_B priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NjtMwELZgkRAXxD-BBRmJG4qaxD9xTqgsVO2utkLaLurNchxnGwmSsG1BvAQvw3vwTMw4SZcitKdYiRNZmfHMN-P5IeS1M7IEoByHsWVgoCTOhsaUPCytioxJTOEc-iFP53J6zo-XYtk73NZ9WOUgE72gLhqLPvJRkoE2YkoI9rb9GmLXKDxd7Vto3CS3sHQZcnW6vDK4OBg_Q6KMkqM16DYQC6ClMKARRnJPGfma_f8Dmv_GS_6lgCb3yN0eOdJxR-r75IarH5Dbp_3Z-EPyc1avqrzCQ3MKYsy1MKJH73lK88qnrtBNQ1sAy18MXZx9jOl62_ooWLem85MQPfh0NpmHv3_RtisDCySj3ypDMfcBPbf4iZWjx-OT0dlivGAU2xl_Nz9ol-tIp7NPdAjuqh-R88mHxdE07LsthJZn6SZkmUlNkguWw4iDVpdWFU54ajmVm8Lw1ORggOSpsaW1Is2FTQpVYKqsyCV7TA7qpnZPCQUMCFYVADeAgyATMiVNGfGU8cjywggZkHj47dr2pcixI8Zn7U0SJXVHKg2k0p5UGt55s3un7QpxXDv7HVJzNxOLaPsbzeWF7vekdgq7GZZgYkrLQeZnNoOrKsvECsciE5DDgRd0v7PX-ooPA_Jq9xj2JJLJ1K7ZwhyVSQXALRYBedKxzm4lTEUsBdwWELXHVHtL3X9SVytf9zvGBkFRxp5dv67n5E6CPO7rUx6Sg83l1r0A5LTJX_rt8Qcx2Bfb priority: 102 providerName: ProQuest |
Title | Inhibitory receptor CD47 binding to plasma TSP1 suppresses NK-cell IFN-γ production via activating the JAK/STAT3 pathway during HIV infection |
URI | https://www.ncbi.nlm.nih.gov/pubmed/38037074 https://www.proquest.com/docview/2902138553 https://www.proquest.com/docview/2896802815 https://pubmed.ncbi.nlm.nih.gov/PMC10688093 https://doaj.org/article/e89369f1406c41119c9c418ff2c5e30a |
Volume | 21 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELb2ISEuiDeBpTISNxQ2iZ85INQuW7W7arXabVHFJXIch0Za0tIHsH-CP8P_4DcxdpJCUcWJS2LFduR4PJlvxp4ZhF4axXMAyqEfagIKSmS0r1RO_VzLQKlIZcZYO-RgyHtjejZhkz3UpDuqJ3C5U7Wz-aTGi-vX3z7fvAWGf-MYXvLjJcgsYHeQPvagIpT4PjoEySRsRoMBlb9j74Ey1DjO7Oy3JZxcDP9dwPPv85N_CKTuXXSnRpK4XZH-Htoz5X10a1DvlT9A3_vltEgLu4mO4bdm5lDCJ--owGnhXFnwaobnAJ4_KTy6ugjxcj13p2LNEg_PfWvRx_3u0P_5A8-rsLBAQvylUNj6QlhLrn3F1OCz9vnx1ag9ItimN_6qbnDl-4h7_fe4OexVPkTj7unopOfX2Rd8TWOx8kmshIpSRlIoUZDyXMvMMEc9I1OVKSpUCgpJKpTOtWYiZTrKZGZdZ1nKySN0UM5K8wRhwISgZQGQA3gI_4hYcpUHVBAaaJopxj0UNtOe6Do0uc2QcZ04FUXypCJVAqRKHKkS6PNq02deBeb4Z-uOpeampQ2q7R7MFh-TmkcTI212wxxUTq4pyIBYx3CXeR5pZkigPHTUrIWkWahJFANKIpIx4qEXm2rgUUsmVZrZGtrImEsAciHz0ONq6WxGQmRABOA4D8mtRbU11O2aspi6OOChTRgUxOTp__i4Z-h2ZDnBRbU8Qgerxdo8B7y1SltoX0xECx12TocXly1ntWg5xoLrZefDL0V2LFA |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3dbtMwFLbGkIAbxD-BAUaCKxQ1iX_iXCBUNqp2XSukdah3nuM4NNKWhrVl2kvwKNzwHjwTx07SUYR2t6tYsR1ZOcfnfMc-Pwi9MYrnAJRDP9QEDJTIaF-pnPq5FoFSkcqMseeQozHvH9H9KZtuoZ9tLIx1q2xlohPU2VzbM_JOlIA2IoIx8qH65tuqUfZ2tS2hUbPF0Fycg8m2eD_YA_q-jaLep8lu32-qCviaJvHSJ4mKVZQykkKLgvbiWmSGuVUZkapM0VilALTTWOlcaxanTEeZyGxIKEs5ge_eQDdB8QbW2IunlwYeBWOrDcwRvLMAXQpiCLSidaCEFt9Qfq5GwP-A7b_-mX8pvN49dLdBqrhbs9Z9tGXKB-jWqLmLf4h-DMpZkRb2kh6D2DQVtPDuHo1xWrhQGbyc4wrA-anCk8PPIV6sKud1axZ4PPTtjQEe9Mb-71-4qtPOAovg74XCNtbCnhTbT8wM3u8OO4eT7oRgWz75XF3gOrYS9wdfcOtMVj5CR9dCh8dou5yX5inCgDnBigOgCPATZFAiuMoDGhMaaJopxj0Utr9d6ib1ua3AcSKdCSS4rEklgVTSkUrCnHfrOVWd-OPK0R8tNdcjbdJu92J-9lU2MkAaYasn5mDSck1BxyQ6gafI80gzQwLloZ2WF2QjSRbyku899HrdDTLAkkmVZr6CMSLhAoBiyDz0pGad9UqICEgMONFDYoOpNpa62VMWM5dnPLQFiYKEPLt6Xa_Q7f5kdCAPBuPhc3QnsvzucmPuoO3l2cq8ANS2TF-6rYLR8XXvzT-OyFa- |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inhibitory+receptor+CD47+binding+to+plasma+TSP1+suppresses+NK-cell+IFN-%CE%B3+production+via+activating+the+JAK%2FSTAT3+pathway+during+HIV+infection&rft.jtitle=Journal+of+translational+medicine&rft.au=Bin+Lang&rft.au=Meiting+Wang&rft.au=Zining+Zhang&rft.au=Yajing+Fu&rft.date=2023-11-30&rft.pub=BMC&rft.eissn=1479-5876&rft.volume=21&rft.issue=1&rft.spage=1&rft.epage=13&rft_id=info:doi/10.1186%2Fs12967-023-04667-6&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_e89369f1406c41119c9c418ff2c5e30a |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon |